Pfizer Inc. provided earnings guidance for the financial year 2023. For the year, the company expected to reported revenue of $67.0 to $71.0 Billion, the revenues Excluding COVID-19 Products Expected to Grow 7% to 9% Operationally Compared to Full-Year 2022 and Revenue Guidance for Comirnaty of $13.5 Billion and Paxlovid of $8 Billion.
Market Closed -
Other stock markets
|
After market 05:41:10 pm | |||
27.7 USD | +1.91% | 27.8 | +0.34% |
09:53pm | PFIZER INC : Buy rating from DZ Bank | ZD |
04:27pm | Morgan Stanley Adjusts Price Target on Pfizer to $29 From $28 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.79% | 154B | |
+29.68% | 699B | |
+25.07% | 571B | |
-4.35% | 364B | |
+17.65% | 326B | |
+3.77% | 286B | |
+14.68% | 236B | |
+4.71% | 198B | |
-12.43% | 194B | |
-3.34% | 149B |
- Stock Market
- Equities
- PFE Stock
- News Pfizer, Inc.
- Pfizer Inc. Provides Earnings Guidance for the Financial Year 2023